Belzutifan given Priority Review status from FDA for von Hippel-Lindau disease-associated renal cell carcinoma

The decision to give priority review for this hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor was based on data from a phase II trial indicating an overall response rate of 36.1%. A marketing authorisation application has not yet been submitted in Europe for this drug.

Source:

Biospace Inc.